Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19:254–67.

Desnoyer A, Broutin S, Delahousse J, Maritaz C, Blondel L, Mir O, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020;128:119–28.

Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019;7:235.

Wesevich A, Goldstein DA, Paydary K, Peer CJ, Figg WD, Ratain MJ. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023;1–8.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med. 2012;366:2443–54.

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer. 2016;4:72.

Chatelut E, Hendrikx JJMA, Martin J, Ciccolini J, Moes DJAR. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect. 2021;9:e00757.

Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol. 2015;33:1430–7.

FDA. Clinical pharmacology and biopharmaceutic review (nivolumab). Application Number 125554Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000ClinPharmR.pdf.

Ratain MJ, Goldstein DA. Time is Money: Optimizing the Scheduling of Nivolumab. Am Soc Clin Oncol; 2018;36:3074–6.

Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, et al. Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. Ann Rev. 2021;61:85–112.

Kimura H, Sone T, Murata A, Koba H, Tambo Y, Hara J, et al. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment. Lung Cancer. 2017;108:7–8.

Kimura H, Araya T, Yoneda T, Shirasaki H, Kurokawa K, Sakai T, et al. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer. Cancer Commun. 2019;39:1–5.

Mari R, Guerin M, Vicier C, Walz J, Bonnet N, Pignot G, et al. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Front Immunol. 2022;13:984132.

Ricciuti B, Metro G, Baglivo S, Colabrese D, Chiari R, Bennati C, et al. Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non–Small Cell Lung Cancer Patient. J Thorac Oncol. 2017;12:e51–5.

Yatsuda Y, Hirose S, Ito Y, Onoda T, Sugiyama Y, Nagafuchi M, et al. A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient. Intern Med. 2021;60:1011–7.

Hirsch I, Goldstein DA, Tannock IF, Butler MO, Gilbert DC. Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. Nat Med. 2022;28:2236–7.

Tang SQ, Tang LL, Mao YP, Li WF, Chen L, Zhang Y, et al. The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Res Treat. 2020;53:339–54.

Gravis G, Marino P, Olive D, Penault-LLorca F, Delord JP, Simon C, et al. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study. BMC Cancer. 2023;23:1–10.

Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, et al. Cross-validation of a multiplex lc-ms/ms method for assaying mabs plasma levels in patients with cancer: A gpco-unicancer study. Pharmaceuticals. 2021;14:796.

Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6:58–66.

Article  CAS  PubMed  Google Scholar 

Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, et al. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Coho. EBioMedicine. 2021;73:103630.

Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ. Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation. J Clin Pharmacol. 2022;62:532–40.

Cloesmeijer ME, van den Oever HLA, Mathôt RAA, Zeeman M, Kruisdijk-Gerritsen A, Bles CMA, et al. Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokinetics. Br J Clin Pharmacol. 2020;86:1620–31.

Economique A HAUTE AUTORITÉ DE SANTÉ EVALUER LES TECHNOLOGIES DE SANTÉ Opdivo (nivolumab) Cancer urothélial infiltrant le muscle à haut risque de récidive.

Zhang J, Sanghavi K, Shen J, Zhao X, Feng Y, Statkevich P, et al. Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies. CPT Pharmacometrics Syst Pharmacol. 2019;8:962–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osawa M, Hasegawa M, Bello A, Roy A, Hruska MW. Population pharmacokinetics analysis of nivolumab in Asian and non-Asian patients with gastric and gastro-esophageal junction cancers. Cancer Chemother Pharmacol. 2019;83:705–15.

Hurkmans DP, Basak EA, Van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019;7:192.

Hamuro L, Statkevich P, Bello A, Roy A, Bajaj G. Nivolumab Clearance is Stationary in Patients with Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance. Clin Pharmacol Ther. 2019;106:1018–27.

Zhang J, Cai J, Bello A, Roy A, Sheng J. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non–Small Cell Lung Cancer. J Clin Pharmacol. 2019;59:1415–24.

Liu C, Yu J, Li H, Liu J, Xu Y, Song P, et al. Association of Time-Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis. Clin Pharmacol Ther. 2017;101:657–66.

Yoo SH, Keam B, Kim M, Kim SH, Kim YJ, Kim TM, et al. Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity. ESMO Open. 2018;3:e000332.

Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study. J Clin Oncol. 2023;41:222–32.

Merrick S, Nankivell M, Quartagno M, Clarke CS, Joharatnam-Hogan N, Waddell T, et al. REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. Contemp Clin Trials. 2023;124:107030.

Tannock IF, Ratain MJ, Goldstein DA, Lichter AS, Rosner GL, Saltz LB. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021;39:950–5.

Marolleau S, Mogenet A, Boeri C, Hamimed M, Ciccolini J, Greillier L. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients. CPT Pharmacometrics Syst Pharmacol. 2023;12:1795–803.

Peer CJ, Schmidt KT, Arisa O, Richardson WJ, Paydary K, Goldstein DA, et al. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation. J Clin Pharmacol. 2023;63:672–80.

Ratain MJ, Peer CJ, Figg WD, Goldstein DA. Dose Optimization of Pembrolizumab: Less May Be More. Clin Pharmacol Ther. 2022;111:993–993.

Millet A, Khoudour N, Bros P, Lebert D, Picard G, Machon C, et al. Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. Talanta. 2021;224:121889.